Stay updated on ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Sign up to get notified when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.

Latest updates to the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; a minor metadata banner change that does not affect content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page no longer displays a notice about government-funding/operational status. This previously advised that information may be out of date and linked to status updates.SummaryDifference0.3%

- Check34 days agoChange DetectedThe new page shows minor formatting tweaks and small text edits without altering core study information such as eligibility criteria, interventions, outcomes, or listed locations.SummaryDifference0.3%

- Check63 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

- Check70 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating a content pruning aligned with a versioned update.SummaryDifference0.2%

Stay in the know with updates to ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.